Halozyme, Inc.

Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference on Wednesday, March 5 at 8:50am PT / 11:50am ET. A live audio webcast will be available here: https://ow.ly/KbjM50VaqOA

Earlier this week, Halozyme full year 2024 record revenue, exceeding its financial guidance for royalty revenue, adjusted EBITDA and Non-GAAP diluted EPS. The significant growth achieved throughout the year culminated in two important milestones for the Company: achievement of more than $1 billion in total revenue and reaching a cumulative one million patients with our ENHANZE drug delivery technology. Additional highlights include: • Record full year 2024 total revenue increased 22% YOY to $1,015 million and record royalty revenue exceeded guidance increasing 27% YOY to $571 million • Full year 2024 net income increased 58% YOY to $444 million; GAAP EPS increased 63% YOY to $3.43; adjusted EBITDA increased 48% YOY to $632 million and non-GAAP EPS increased 53% YOY to $4.231, both exceeding guidance • Reiterating 2025 financial guidance ranges for total revenue of $1,150 - 1,225 million, representing YOY growth of 13% - 21%, adjusted EBITDA of $755 - $805 million, representing YOY growth of 19% - 27% and non-GAAP diluted EPS of $4.95 - $5.35, representing YOY growth of 17% - 26%1 More details are available here: https://ow.ly/LOfO50V3J4k Footnotes: 1. Amounts relate to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition.

Yesterday, we hosted an Investor Conference Call during which we reiterated our 2024 financial guidance and raised 2025 and multi-year financial guidance. Highlights include: • We reported preliminary 2024 unaudited estimated ranges consistent with previous financial guidance • We raised 2025 financial guidance ranges for total revenue to $1,150 - $1,225 million, representing YoY growth of 16% - 23%; adjusted EBITDA of $755 - $805 million, representing YoY growth of 24% - 32%; and non-GAAP diluted EPS of $4.95 - $5.35, representing YoY growth of 21% - 30% • Announced a new $250 million accelerated share repurchase For additional information, please visit: https://ow.ly/y7O850UCPS7

We’re closing out 2024 with some exciting news from our partners argenx, Bristol Myers Squibb and Takeda. Check out our latest news here: https://ow.ly/hrvS50UyrHp We appreciate the opportunity to continue to provide patients with more flexible treatment options with our innovative drug delivery technology and look forward to continuing to support patients and our partners in 2025 and beyond. Happy New Year!

Members of the executive leadership team are scheduled to present and host investor meetings at the Piper Sandler 36th Annual Healthcare Conference and the 7th Annual Evercore ISI HealthCONx Conference. To learn more: https://ow.ly/aJjg50Ukb0K

Last week, Halozyme reported financial and operating results for the third quarter and provided an update on our recent corporate activities and outlook. Highlights include: • Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million • Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million • GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271 • Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-52% More details are available here: https://ow.ly/u4yj50TZPeN Footnotes: 1. Reconciliations between GAAP reported and non-GAAP financial information for actual results are provided at the end.

Halozyme to Report Third Quarter 2024 Financial and Operating Results Earlier today, we announced that we will share our third quarter 2024 financial and operating results on Thursday, October 31 following the close of trading. https://ow.ly/LRpK50TS8pR

Attending PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2024 this week? Join David Kang at 10:55 today to learn a more about using a Miniature Pig as a Preclinical Model to Predict the Clinical Injection Times of a 10 mL High-volume Auto-injector (HVAI) with Recombinant Human Hyaluronidase (rHuPH20). Have questions? Stop by booth #925 to learn more. #PDAups #subcutaneous #Halozyme

Attending PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2024 tomorrow? Join David Kang at 11:30 to learn more about Challenges and Opportunities with Rapid Handheld Injections (> 2mL) and the Clinical Tolerability of a 10 mL High-Volume Auto-Injector. Have questions? Stop by booth #925 to learn more. #PDAups #subcutaneous #HVAI #Halozyme

Join us at Sexual Medicine Society of North America (SMSNA) tomorrow, Friday, October 18 at 7 am to learn how testosterone replacement may fit into your treatment approach. #halozyme #SMSNA24